RxDoctor Payments Data

Sarah Woodruff

Family · Chapel Hill, NCNPI 1295982866

Payments from drug & device makers

$1,888in general payments, 2019–2025

Across 82 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$432
  • Abbott$367
  • Lilly USA, LLC$237
  • AstraZeneca$205
  • AbbVie$200
  • Pfizer$157
  • plus $289 from 8 others

What the payments were for

  • Food & beverage$1,888100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,888 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$19,684
Medicare patients
50
Services billed
315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide16$27,450
JardianceEmpagliflozin18$13,811
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,302
FarxigaDapagliflozin Propanediol13$10,167
Atorvastatin Calcium84$646
Amlodipine Besylate43$471
Tamsulosin Hcl21$347
Rosuvastatin Calcium30$282
Omeprazole27$272
Finasteride14$252
Albuterol Sulfate HfaAlbuterol Sulfate17$243
Levothyroxine Sodium29$204
Metoprolol Succinate18$199
Gabapentin16$182
Lisinopril40$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$237$27,45016 claims
AstraZenecaFarxiga$205$10,16713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.

Other family in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →